A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children’s Oncology Group

PURPOSE: Evaluate the clinical safety, toxicity, immune activation/modulation, and maximal tolerated dose of hu14.18-IL2 (EMD 273063) in pediatric patients with recurrent/refractory neuroblastoma and other GD2-positive solid tumors. EXPERIMENTAL DESIGN: Twenty-seven pediatric patients with recurrent...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Osenga, Kaci L., Hank, Jacquelyn A., Albertini, Mark R., Gan, Jacek, Sternberg, Adam G., Eickhoff, Jens, Seeger, Robert C., Matthay, Katherine K., Reynolds, C. Patrick, Twist, Clare, Krailo, Mark, Adamson, Peter C., Reisfeld, Ralph A., Gillies, Stephen D., Sondel, Paul M.
Format: Artigo
Idioma:Inglês
Publicat: 2006
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2587020/
https://ncbi.nlm.nih.gov/pubmed/16551859
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-05-2000
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars